Accurately diagnosing neurodegenerative dementia is often challenging due to overlapping clinical features. Disease specific biomarkers could enhance diagnostic accuracy. However, CSF analysis procedures and advanced imaging modalities are either invasive or high-priced, and routinely unavailable. Easily accessible disease biomarkers would be of utmost value for accurate differential diagnosis of dementia subtypes.
Objective
To assess the diagnostic accuracy of blood-based biomarkers for the differential diagnosis of AD from Frontotemporal Lobar Degeneration (FTLD), or AD from Dementia with Lewy Bodies (DLB).
Methods
Systematic review. Three databases (PubMed, Scopus, and Web of Science) were searched. Studies assessing blood-based biomarkers levels in AD versus FTLD, or AD versus DLB, and its diagnostic accuracy, were selected. When the same biomarker was assessed in three or more studies, a meta-analysis was performed. QUADAS-2 criteria were used for quality assessment.
Results
Twenty studies were included in this analysis. Collectively, 905 AD patients were compared to 1262 FTLD patients, and 209 AD patients were compared to 246 DLB patients. Regarding biomarkers for AD versus FTLD, excellent discriminative accuracy (AUC >0.9) was found for p-tau181, p-tau217, synaptophysin, synaptopodin, GAP43 and calmodulin. Other biomarkers also demonstrated good accuracy (AUC = 0.8-0.9). For AD versus DLB distinction, only miR-21-5p and miR-451a achieved excellent accuracy (AUC >0.9).
Conclusion
Encouraging results were found for several biomarkers, alone or in combination. Prospective longitudinal designs and consensual protocols, comprising larger cohorts and homogeneous testing modalities across centres, are essential to validate the clinical value of blood biomarkers for the precise etiological diagnosis of dementia.
ErkkinenMGKimMOGeschwindMD. Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol. 2018;10(4):a033118.
2.
ReitzCBrayneCMayeuxR. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7(3):137-152.
3.
MayeuxRSternY. Epidemiology of Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(8):a006239.
4.
Soria LopezJAGonzálezHMLégerGC. Alzheimer’s disease. Handb Clin Neurol. 2019;167:231-255.
5.
RazLKnoefelJBhaskarK. The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab. 2016;36(1):172-186.
6.
SanfordAM. Lewy body dementia. Clin Geriatr Med. 2018;34(4):603-615.
ElahiFMMillerBL. A clinicopathological approach to the diagnosis of dementia. Nat Rev Neurol. 2017;13(8):457-476.
11.
GompertsSN. Lewy body dementias: Dementia with lewy bodies and Parkinson disease dementia. Continuum (Minneap Minn). 2016;22(2):435-463.
12.
JellingerKA. Dementia with Lewy bodies and Parkinson’s disease-dementia: Current concepts and controversies. J Neural Transm (Vienna). 2018;125(4):615-650.
13.
KonTTomiyamaMWakabayashiK. Neuropathology of Lewy body disease: Clinicopathological crosstalk between typical and atypical cases. Neuropathology. 2020;40(1):30-39.
14.
DeTureMADicksonDW. The neuropathological diagnosis of Alzheimer’s disease. Mol Neurodegener. 2019;14(1):32.
15.
ChinKSTeodorczukAWatsonR. Dementia with Lewy bodies: Challenges in the diagnosis and management. Aust N Z J Psychiatry. 2019;53(4):291-303.
Rodriguez-VieitezENielsenHM. Associations between APOE variants, Tau and α-Synuclein. Adv Exp Med Biol. 2019;1184:177-186.
18.
VillainNDuboisB. Alzheimer’s disease including focal presentations. Semin Neurol. 2019;39(2):213-226.
19.
Grandal LeirosBPérez MéndezLIZelaya HuertaMV, et al.Prevalence and concordance between the clinical and the post-mortem diagnosis of dementia in a psychogeriatric clinic. Neurologia (Engl Ed). 2018;33(1):13-17.
20.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263-269.
21.
McKeithIGBoeveBFDicksonDW, et al.Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100.
RascovskyKHodgesJRKnopmanD, et al.Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(9):2456-2477.
24.
BeachTGMonsellSEPhillipsLEKukullW. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71(4):266-273.
25.
RizzoGArcutiSCopettiM, et al.Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2018;89(4):358-366.
26.
MendezMFShapiraJSMcMurtrayALichtEMillerBL. Accuracy of the clinical evaluation for frontotemporal dementia. Arch Neurol. 2007;64(6):830-835.
27.
ZhuCWOrnsteinKACosentinoSGuYAndrewsHSternY. Misidentification of dementia in medicare claims and related costs. J Am Geriatr Soc. 2019;67(2):269-276.
28.
BradfordAKunikMESchulzPWilliamsSPSinghH. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord. 2009;23(4):306-314.
29.
GauglerJEAscher-SvanumHRothDLFafoworaTSiderowfABeachTG. Characteristics of patients misdiagnosed with Alzheimer’s disease and their medication use: an analysis of the NACC-UDS database. BMC Geriatr. 2013;13:137.
30.
AhmedRMPatersonRWWarrenJD, et al.Biomarkers in dementia: Clinical utility and new directions. J Neurol Neurosurg Psychiatry. 2014;85(12):1426-1434.
31.
AronsonJKFernerRE. Biomarkers-A general review. Curr Protoc Pharmacol. 2017;76:9-23.
32.
DuboisBFeldmanHHJacovaC, et al.Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-746.
33.
SimonsenAHHerukkaS-KAndreasenN, et al.Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer’s & Dementia. 2017;13(3):274-284.
34.
FengLLiJZhangR. Current research status of blood biomarkers in Alzheimer’s disease: Diagnosis and prognosis. Ageing Res Rev. 2021;72:101492.
35.
AusóEGómez-VicenteVEsquivaG. Biomarkers for Alzheimer’s disease early diagnosis. J Pers Med. 2020;10(3):114.
36.
TeunissenCEVerberkIMWThijssenEH, et al.Blood-based biomarkers for Alzheimer’s disease: Towards clinical implementation. Lancet Neurol. 2022;21(1):66-77.
37.
HampelHO’BryantSEMolinuevoJL, et al.Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol. 2018;14(11):639-652.
KarantaliEKazisDChatzikonstantinouSPetridisFMavroudisI. The role of neurofilament light chain in frontotemporal dementia: A meta-analysis. Aging Clin Exp Res. 2021;33(4):869-881.
40.
SchneiderL. A resurrection of aducanumab for Alzheimer’s disease. Lancet Neurol. 2020;19(2):111-112.
41.
TolarMAbushakraSHeyJAPorsteinssonASabbaghM. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimers Res Ther. 2020;12(1):95.
42.
BehlTKaurISehgalA, et al.Aducanumab making a comeback in Alzheimer’s disease: An old wine in a new bottle. Biomed Pharmacother. 2022;148:112746.
43.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
44.
WhitingPFRutjesAWWestwoodME, et al.QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529-536.
45.
HigginsJPTThompsonSGDeeksJJAltmanDG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-560.
46.
WanXWangWLiuJTongT. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
47.
HigginsJPT LTDeeksJJ. Chapter 6: Choosing effect measures and computing estimates of effect. In: HigginsJPTThomasJChandlerJCumpstonMLiTPageMJWelchVA (editors) Cochrane Handbook for Systematic Reviews of Interventions version 63. Cochrane; 2022.
48.
WeirCJButcherIAssiV, et al.Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: A systematic review. BMC Med Res Methodol. 2018;18(1):25.
49.
XiaJBroadhurstDIWilsonMWishartDS. Translational biomarker discovery in clinical metabolomics: An introductory tutorial. Metabolomics. 2013;9(2):280-299.
50.
KarikariTKPascoalTAAshtonNJ, et al.Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422-433.
51.
PalmqvistSJanelidzeSQuirozYT, et al.Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. Jama. 2020;324(8):772-781.
52.
ThijssenEHLa JoieRStromA, et al.Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study. Lancet Neurol. 2021;20(9):739-752.
53.
BenussiAKarikariTKAshtonN, et al.Diagnostic and prognostic value of serum NfL and p-Tau(181) in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2020;91(9):960-967.
54.
ThijssenEHLa JoieRWolfA, et al.Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387-397.
55.
AshtonNJJanelidzeSAl KhleifatA, et al.A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12(1):3400.
56.
Illán-GalaILleoAKarydasA, et al.Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease. Neurology. 2021;96(5):e671-e683.
57.
ZerrIVillar-PiquéAHermannP, et al.Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. Alzheimers Res Ther. 2021;13(1):86.
58.
SteinackerPAnderl-StraubSDiehl-SchmidJ, et al.Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology. 2018;91(15):e1390-e1401.
59.
PiscopoPGrassoMPuopoloM, et al.Circulating miR-127-3p as a potential biomarker for differential diagnosis in frontotemporal dementia. J Alzheimers Dis. 2018;65(2):455-464.
60.
SheinermanKSToledoJBTsivinskyVG, et al.Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. Alzheimers Res Ther. 2017;9(1):89.
61.
GoetzlEJKapogiannisDSchwartzJB, et al.Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease. Faseb J. 2016;30(12):4141-4148.
62.
OecklPHalbgebauerSAnderl-StraubS, et al.Targeted mass spectrometry suggests beta-synuclein as synaptic blood marker in Alzheimer’s disease. J Proteome Res. 2020;19(3):1310-1318.
63.
OecklPHalbgebauerSAnderl-StraubS, et al.Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67(2):481-488.
64.
LlorensFVillar-PiquéASchmitzM, et al.Plasma total prion protein as a potential biomarker for neurodegenerative dementia: Diagnostic accuracy in the spectrum of prion diseases. Neuropathol Appl Neurobiol. 2020;46(3):240-254.
65.
EsterasNAlquézarCde la EncarnaciónAVillarejoABermejo-ParejaFMartín-RequeroA. Calmodulin levels in blood cells as a potential biomarker of Alzheimer’s disease. Alzheimers Res Ther. 2013;5(6):55.
66.
MollenhauerBSteinackerPBahnE, et al.Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis. 2007;4(5):366-375.
67.
Wada-IsoeKImamuraKKitamayaMKowaHNakashimaK. Serum heart-fatty acid binding protein levels in patients with Lewy body disease. J Neurol Sci. 2008;266(1-2):20-24.
68.
Gámez-ValeroACampdelacreuJVilasD, et al.Exploratory study on microRNA profiles from plasma-derived extracellular vesicles in Alzheimer’s disease and dementia with Lewy bodies. Transl Neurodegener. 2019;8:31.
69.
LaskeCFallgatterAJStranskyEHagenKBergDMaetzlerW. Decreased α-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer’s disease patients and control subjects. Dement Geriatr Cogn Disord. 2011;31(6):413-416.
70.
SchulzIKruseNGeraRG, et al.Systematic assessment of 10 biomarker candidates focusing on α-synuclein-related disorders. Mov Disord. 2021;36(12):2874-2887.
71.
JanelidzeSMattssonNPalmqvistS, et al.Plasma P-tau181 in Alzheimer’s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat Med. 2020;26(3):379-386.
72.
MoscosoAGrotheMJAshtonNJ, et al.Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum. Brain. 2021;144(1):325-339.
73.
KarikariTKBenedetALAshtonNJ, et al.Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s disease neuroimaging initiative. Mol Psychiatry. 2021;26(2):429-442.
74.
HampelHBlennowKShawLMHoesslerYCZetterbergHTrojanowskiJQ. Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Exp Gerontol. 2010;45(1):30-40.
75.
TangWHuangQYaoYYWangYWuYLWangZY. Does CSF p-tau181 help to discriminate Alzheimer’s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature. J Neural Transm (Vienna). 2014;121(12):1541-1553.
76.
JanelidzeSStomrudESmithR, et al.Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease. Nat Commun. 2020;11(1):1683.
77.
HanssonO. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954-963.
78.
LeuzyAJanelidzeSMattsson-CarlgrenN, et al.Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 assays. Neurology. 2021;97(17):e1681-e1694.
79.
VerdeF. Tau proteins in blood as biomarkers of Alzheimer’s disease and other proteinopathies. J Neural Transm (Vienna). 2022;129(2):239-259.
80.
Mattsson-CarlgrenNJanelidzeSBatemanRJ, et al.Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med. 2021;13(6):e14022.
81.
JanelidzeSBerronDSmithR, et al.Associations of plasma Phospho-Tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol. 2021;78(2):149-156.
82.
Mattsson-CarlgrenNJanelidzeSPalmqvistS, et al.Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease. Brain. 2020;143(11):3234-3241.
83.
BarthélemyNRLiYJoseph-MathurinN, et al.A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat Med. 2020;26(3):398-407.
84.
RitchieCSmailagicNNoel-StorrAHUkoumunneOLaddsECMartinS. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017;3(3):Cd010803.
85.
HampelHTeipelSJ. Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord. 2004;17(4):350-354.
86.
ScarafinoAD’ErricoEIntronaA, et al.Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis. J Neurol. 2018;265(10):2353-2362.
87.
MeeterLHHVijverbergEGDel CampoM, et al.Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology. 2018;90(14):e1231-e1239.
88.
SkaperSDFacciLZussoMGiustiP. Synaptic plasticity, dementia and Alzheimer disease. CNS Neurol Disord Drug Targets. 2017;16(3):220-233.
89.
JamshidiPKimGShahidehpourRK, et al.Distribution of TDP-43 pathology in hippocampal synaptic relays suggests transsynaptic propagation in frontotemporal lobar degeneration. J Neuropathol Exp Neurol. 2020;79(6):585-591.
90.
SalmonEBahriMAPlenevauxA, et al.In vivo exploration of synaptic projections in frontotemporal dementia. Scientific Rep. 2021;11(1):16092.
91.
ScheltensPBlennowKBretelerMM, et al.Alzheimer’s disease. Lancet. 2016;388(10043):505-517.
92.
KvartsbergHDuitsFHIngelssonM, et al.Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimers Dement. 2015;11(10):1180-1190.
93.
WangL. Association of cerebrospinal fluid Neurogranin with Alzheimer’s disease. Aging Clin Exp Res. 2019;31(2):185-191.
94.
BohushALeśniakWWeisSFilipekA. Calmodulin and its binding proteins in Parkinson’s disease. Int J Mol Sci. 2021;22(6).
95.
EsterasNAlquézarCBermejo-ParejaFBialopiotrowiczEWojdaUMartín-RequeroA. Downregulation of extracellular signal-regulated kinase 1/2 activity by calmodulin KII modulates p21Cip1 levels and survival of immortalized lymphocytes from Alzheimer’s disease patients. Neurobiol Aging. 2013;34(4):1090-1100.
96.
García-OstaADongJMoreno-AliagaMJRamirezMJ. The cell cycle and Alzheimer’s disease. Int J Mol Sci. 2022;23(3).
97.
VillaloboABerchtoldMW. The role of calmodulin in tumor cell migration, invasiveness, and metastasis. Int J Mol Sci. 2020;21(3).
98.
MuñozUBartoloméFBermejoFMartín-RequeroA. Enhanced proteasome-dependent degradation of the CDK inhibitor p27(kip1) in immortalized lymphocytes from Alzheimer’s dementia patients. Neurobiol Aging. 2008;29(10):1474-1484.
99.
BartoloméFde Las CuevasNMuñozUBermejoFMartín-RequeroA. Impaired apoptosis in lymphoblasts from Alzheimer’s disease patients: cross-talk of Ca2+/calmodulin and ERK1/2 signaling pathways. Cell Mol Life Sci. 2007;64(11):1437-1448.
100.
O’DayDH. Calmodulin binding proteins and Alzheimer’s disease: Biomarkers, regulatory enzymes and receptors that are regulated by calmodulin. Int J Mol Sci. 2020;21(19).
101.
CenJLiangYHuangY, et al.Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis. Mol Cancer. 2021;20(1):19.
102.
ZhangZBXiongLLXueLL, et al.MiR-127-3p targeting CISD1 regulates autophagy in hypoxic-ischemic cortex. Cell Death Dis. 2021;12(3):279.
103.
HeQQXiongLLLiuF, et al.MicroRNA-127 targeting of mitoNEET inhibits neurite outgrowth, induces cell apoptosis and contributes to physiological dysfunction after spinal cord transection. Sci Rep. 2016;6:35205.
104.
RonquilloJGBaerMRLesterWT. Sex-specific patterns and differences in dementia and Alzheimer’s disease using informatics approaches. J Women Aging. 2016;28(5):403-411.
105.
SharmaSEghbaliM. Influence of sex differences on microRNA gene regulation in disease. Biol Sex Differ. 2014;5(1):3.
106.
ZiatsMNRennertOM. Identification of differentially expressed microRNAs across the developing human brain. Mol Psychiatry. 2014;19(7):848-852.
107.
KamphuisWMiddeldorpJKooijmanL, et al.Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer’s disease. Neurobiol Aging. 2014;35(3):492-510.
108.
BenedetALMilà-AlomàMVrillonA, et al.Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78(12):1471-1483.
109.
PereiraJBJanelidzeSSmithR, et al.Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease. Brain. 2021;144(11):3505-3516.
110.
MiddeldorpJHolEM. GFAP in health and disease. Prog Neurobiol. 2011;93(3):421-443.
111.
FukuyamaRIzumotoTFushikiS. The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer’s disease patients and correlates with severity of dementia. Eur Neurol. 2001;46(1):35-38.
112.
BellaverBFerrari-SouzaJPUglione da RosL, et al.Astrocyte biomarkers in Alzheimer Disease: A systematic review and meta-analysis. Neurology. 2021.
113.
MattssonNCullenNCAndreassonUZetterbergHBlennowK. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2019;76(7):791-799.
114.
MattssonNAndreassonUZetterbergHBlennowK. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74(5):557-566.
115.
ContadorJPérez-MillánATort-MerinoA, et al.Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer’s disease. Neuroimage Clin. 2021;32:102804.
116.
VerdeFOttoMSilaniV. Neurofilament light chain as biomarker for amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 2021;15:679199.
117.
KhalilMTeunissenCEOttoM, et al.Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol. 2018;14(10):577-589.
118.
SampedroFPérez-PérezJMartínez-HortaS, et al.Cortical microstructural correlates of plasma neurofilament light chain in Huntington’s disease. Parkinsonism Relat Disord. 2021;85:91-94.
119.
HajiSSakoWMurakamiNOsakiYIzumiY. Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis. J Neural Transm (Vienna). 2022.
120.
ZhaoYXinYMengSHeZHuW. Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis. Neurosci Biobehav Rev. 2019;102:123-138.
121.
OecklPMetzgerFNaglM, et al.Alpha-, beta-, and gamma-synuclein quantification in cerebrospinal fluid by multiple reaction monitoring reveals increased concentrations in Alzheimer’s and creutzfeldt-jakob disease but no alteration in synucleinopathies. Mol Cell Proteomics. 2016;15(10):3126-3138.
122.
VölkelDZimmermannKZerrI, et al.Immunochemical determination of cellular prion protein in plasma from healthy subjects and patients with sporadic CJD or other neurologic diseases. Transfusion. 2001;41(4):441-448.
123.
SchröderBFranzBHempflingP, et al.Polymorphisms within the prion-like protein gene (Prnd) and their implications in human prion diseases, Alzheimer’s disease and other neurological disorders. Hum Genet. 2001;109(3):319-325.
124.
D’ArgenioVSarnataroD. Microbiome influence in the pathogenesis of prion and Alzheimer’s diseases. Int J Mol Sci. 2019;20(19).
125.
Abu RumeilehSLattanzioFStanzani MaseratiMRizziRCapellariSParchiP. Diagnostic accuracy of a combined analysis of cerebrospinal fluid t-PrP, t-tau, p-tau, and Aβ42 in the differential diagnosis of creutzfeldt-jakob disease from Alzheimer’s disease with emphasis on atypical disease variants. J Alzheimers Dis. 2017;55(4):1471-1480.
126.
HillAF. Extracellular vesicles and neurodegenerative diseases. J Neurosci. 2019;39(47):9269-9273.
127.
WangXZhouYGaoQ, et al.The role of exosomal microRNAs and oxidative stress in neurodegenerative diseases. Oxid Med Cell Longev. 2020;2020:3232869.
128.
GuiYLiuHZhangLLvWHuX. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. Oncotarget. 2015;6(35):37043-37053.
129.
McKeeverPMSchneiderRTaghdiriF, et al.MicroRNA expression levels are altered in the cerebrospinal fluid of patients with young-onset Alzheimer’s disease. Mol Neurobiol. 2018;55(12):8826-8841.
130.
SørensenSSNygaardABChristensenT. miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia - an exploratory study. Transl Neurodegener. 2016;5:6.
131.
VacchiEKaelin-LangAMelliG. Tau and alpha synuclein synergistic effect in neurodegenerative diseases: When the periphery is the core. Int J Mol Sci. 2020;21(14).
132.
BurréJSharmaMSüdhofTC. Cell biology and pathophysiology of α-synuclein. Cold Spring Harb Perspect Med. 2018;8(3).
133.
KasugaKNishizawaMIkeuchiT. α-Synuclein as CSF and blood biomarker of dementia with lewy bodies. Int J Alzheimers Dis. 2012;2012:437025.
134.
SteinerJBogertsBSchroeterMLBernsteinHG. S100B protein in neurodegenerative disorders. Clin Chem Lab Med. 2011;49(3):409-424.
135.
Suárez-CalvetMMorenas-RodríguezEKleinbergerG, et al.Early increase of CSF sTREM2 in Alzheimer’s disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Mol Neurodegener. 2019;14(1):1.
136.
WilczyńskaKWaszkiewiczN. Diagnostic utility of selected serum dementia biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A review. J Clin Med. 2020;9(11).
137.
GaetaniLBlennowKCalabresiPDi FilippoMParnettiLZetterbergH. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019;90(8):870-881.
138.
LlorensFThüneKTahirW, et al.YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017;12(1):83.
139.
WennströmMSurovaYHallS, et al.The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer’s but not Parkinson’s disease or dementia with lewy bodies. PLoS One. 2015;10(8):e0135458.
140.
WangLGaoTCaiTLiKZhengPLiuJ. Cerebrospinal fluid levels of YKL-40 in prodromal Alzheimer’s disease. Neurosci Lett. 2020;715:134658.
141.
BaldacciFListaSPalermoGGiorgiFSVergalloAHampelH. The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: Advances in development. Expert Rev Proteomics. 2019;16(7):593-600.
142.
MuszyńskiPGroblewskaMKulczyńska-PrzybikAKułakowskaAMroczkoB. YKL-40 as a potential biomarker and a possible target in therapeutic strategies of Alzheimer’s disease. Curr Neuropharmacol. 2017;15(6):906-917.
143.
HellwigKKvartsbergHPorteliusE, et al.Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease. Alzheimers Res Ther. 2015;7:74.
144.
SteinackerPMollenhauerBBiblM, et al.Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett. 2004;370(1):36-39.
145.
DesikanRSThompsonWKHollandD, et al.Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration. Mol Neurodegener. 2013;8:39.
146.
YousafTDervenoulasGValkimadiPEPolitisM. Neuroimaging in Lewy body dementia. J Neurol. 2019;266(1):1-26.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
